Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | 1,2-dimethylhydrazine | increases expression | ISO | Svopl (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in increased expression of SVOPL mRNA | CTD | PMID:22206623 | 2,3',4,4',5-Pentachlorobiphenyl | increases expression | ISO | Svopl (Mus musculus) | 6480464 | 2 more ... | CTD | PMID:31388691 | 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | Svopl (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin promotes the reaction [AHR protein binds to SVOPL promoter] | CTD | PMID:19654925 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Svopl (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SVOPL mRNA | CTD | PMID:32109520 | 4,4'-sulfonyldiphenol | decreases expression | ISO | Svopl (Mus musculus) | 6480464 | bisphenol S results in decreased expression of SVOPL mRNA | CTD | PMID:33297965 | benzo[a]pyrene | decreases methylation | ISO | Svopl (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased methylation of SVOPL promoter | CTD | PMID:27901495 | benzo[a]pyrene | increases methylation | EXP | | 6480464 | Benzo(a)pyrene results in increased methylation of SVOPL promoter | CTD | PMID:27901495 | bisphenol A | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of SVOPL gene | CTD | PMID:31601247 | bortezomib | decreases expression | EXP | | 6480464 | Bortezomib results in decreased expression of SVOPL mRNA | CTD | PMID:20977926 | cyclosporin A | increases methylation | EXP | | 6480464 | Cyclosporine results in increased methylation of SVOPL promoter | CTD | PMID:27989131 | diquat | increases expression | ISO | Svopl (Mus musculus) | 6480464 | Diquat results in increased expression of SVOPL mRNA | CTD | PMID:36851058 | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SVOPL mRNA | CTD | PMID:27188386 | entinostat | increases expression | EXP | | 6480464 | entinostat results in increased expression of SVOPL mRNA | CTD | PMID:26272509 | entinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SVOPL mRNA | CTD | PMID:27188386 | fulvestrant | multiple interactions | EXP | | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of SVOPL gene | CTD | PMID:31601247 | fulvestrant | increases methylation | EXP | | 6480464 | Fulvestrant results in increased methylation of SVOPL gene | CTD | PMID:31601247 | genistein | decreases expression | ISO | Svopl (Mus musculus) | 6480464 | Genistein results in decreased expression of SVOPL mRNA | CTD | PMID:32186404 | pentanal | decreases expression | EXP | | 6480464 | pentanal results in decreased expression of SVOPL mRNA | CTD | PMID:26079696 | pioglitazone | multiple interactions | ISO | Svopl (Mus musculus) | 6480464 | [N-nitroso-tris-chloroethylurea co-treated with pioglitazone] results in decreased expression of SVOPL mRNA | CTD | PMID:27935865 | S-(1,2-dichlorovinyl)-L-cysteine | increases expression | EXP | | 6480464 | S-(1 and 2-dichlorovinyl)cysteine results in increased expression of SVOPL mRNA | CTD | PMID:35811015 | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SVOPL mRNA | CTD | PMID:27188386 | silicon dioxide | decreases expression | EXP | | 6480464 | Silicon Dioxide analog results in decreased expression of SVOPL mRNA | CTD | PMID:25895662 | sodium arsenite | decreases expression | ISO | Svopl (Mus musculus) | 6480464 | sodium arsenite results in decreased expression of SVOPL mRNA | CTD | PMID:36209798 and PMID:37682722 | Theaflavin 3,3'-digallate | affects expression | EXP | | 6480464 | theaflavin-3 and 3'-digallate affects the expression of SVOPL mRNA | CTD | PMID:34925699 | trichloroethene | increases expression | ISO | Svopl (Rattus norvegicus) | 6480464 | Trichloroethylene results in increased expression of SVOPL mRNA | CTD | PMID:33387578 | trimellitic anhydride | decreases expression | ISO | Svopl (Mus musculus) | 6480464 | trimellitic anhydride results in decreased expression of SVOPL mRNA | CTD | PMID:19042947 | triptonide | increases expression | ISO | Svopl (Mus musculus) | 6480464 | triptonide results in increased expression of SVOPL mRNA | CTD | PMID:33045310 | valproic acid | increases methylation | EXP | | 6480464 | Valproic Acid results in increased methylation of SVOPL gene | CTD | PMID:29154799 | valproic acid | decreases expression | ISO | Svopl (Rattus norvegicus) | 6480464 | Valproic Acid results in decreased expression of SVOPL mRNA | CTD | PMID:35594946 | XL147 | multiple interactions | ISO | Svopl (Mus musculus) | 6480464 | [N-nitroso-tris-chloroethylurea co-treated with XL147] results in decreased expression of SVOPL mRNA | CTD | PMID:27935865 | |